Collaboration and License Agreements - Additional Information (Details) - USD ($) shares in Millions |
1 Months Ended | 3 Months Ended | 6 Months Ended | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
Oct. 31, 2023 |
Sep. 30, 2022 |
Dec. 31, 2021 |
Jun. 30, 2021 |
Jun. 30, 2025 |
Jun. 30, 2024 |
Jun. 30, 2025 |
Jun. 30, 2024 |
Dec. 31, 2024 |
Jun. 30, 2022 |
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||
| Current portion of deferred revenue | $ 105,822,000 | $ 105,822,000 | $ 108,858,000 | |||||||
| Long-term portion of deferred revenue | 20,319,000 | 20,319,000 | $ 33,218,000 | |||||||
| Lilly Agreement | ||||||||||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||
| Agreement description | In October 2023, the Company entered into a Transfer and Delegation Agreement, or the Lilly Agreement, with Eli Lilly and Company, or Lilly, pursuant to which Lilly acquired certain assets and other rights under the Company’s amended collaboration and license agreement, or the Verve Agreement, with Verve Therapeutics, Inc., or Verve, including the Company’s opt-in rights to co-develop and co-commercialize Verve’s base editing programs for cardiovascular disease (see discussion below related to the Verve Agreement). The Company granted Lilly an exclusive sublicense to the Verve technology originally licensed to the Company under the Verve Agreement. Lilly also acquired the right to receive any future milestone or royalty payments payable by Verve under the Verve Agreement and the rights and obligations to designate representatives and participate on the joint steering committee with Verve. The Company received a $200.0 million nonrefundable upfront payment and is eligible to receive up to $350.0 million in potential future development-stage payments upon the completion of certain clinical, regulatory and alliance events, of which $25.0 million has been received through June 30, 2025. | |||||||||
| Collaboration agreement upfront payment received | $ 200,000,000 | |||||||||
| Collaboration agreement milestones payment received | 25,000,000 | 25,000,000 | ||||||||
| Collaboration agreement performance obligation revenue recognized | 0 | 0 | ||||||||
| Deferred revenue liability | 0 | 0 | ||||||||
| Lilly Agreement | Maximum | ||||||||||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||
| Additional proceeds from potential future development-stage payments | $ 350,000,000 | |||||||||
| Pfizer | ||||||||||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||
| Agreement description | In December 2021, the Company entered into a research collaboration agreement, or the Pfizer Agreement, with Pfizer Inc., or Pfizer, focused on the use of certain of the Company’s base editing technology to develop in vivo therapies for rare genetic diseases of the liver, muscle, and central nervous system. Under the terms of the Pfizer Agreement, the Company will conduct all research activities through development candidate selection for three base editing programs that target specific genes corresponding to specific diseases that are the subject of such programs. Pfizer will have exclusive rights to license each of the three programs at no additional cost, each an Opt-In Right, and will assume responsibility for subsequent development and commercialization. At the end of the Phase 1/2 clinical trials, the Company may elect to enter into a global co-development and co-commercialization agreement with Pfizer with respect to one program licensed under the collaboration for an option exercise fee equal to a percentage of the applicable development costs incurred by Pfizer, or the Participation Election. In the event the Company elects to exercise its Participation Election, upon the payment of its option exercise fee, Pfizer and the Company would share net profits as well as development and commercialization costs in a 65%/35% (Pfizer/Company) split for such program. The research collaboration is managed on an overall basis by a Joint Research Committee, or JRC, formed by an equal number of representatives from the Company and Pfizer. | |||||||||
| Collaboration arrangement, initial term | 4 years | |||||||||
| Collaboration arrangement, extended month and year | 2025-12 | |||||||||
| Collaboration arrangement, option to extend | The initial four year term of the collaboration extends through December 2025 with an option to extend for an additional year. | |||||||||
| Collaboration arrangement extension term description | extended for an additional year on a program-by-program basis | |||||||||
| Potential total consideration | $ 1,350,000,000 | |||||||||
| Collaboration agreement aggregate transaction price | 300,000,000 | |||||||||
| Nonrefundable upfront payment receivable | $ 300,000,000 | |||||||||
| Collaboration agreement performance obligation revenue recognized | 0 | $ 6,300,000 | 0 | $ 5,700,000 | ||||||
| Earn-out payment period | 10 years | |||||||||
| Current portion of deferred revenue | 88,800,000 | 88,800,000 | ||||||||
| Long-term portion of deferred revenue | 20,300,000 | 20,300,000 | ||||||||
| Pfizer | Assigned to Company | Upon Participation Election | ||||||||||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||
| Net profits as well as development and commercialization costs percentage | 35.00% | |||||||||
| Pfizer | Assigned to Pfizer | Upon Participation Election | ||||||||||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||
| Net profits as well as development and commercialization costs percentage | 65.00% | |||||||||
| Pfizer | Maximum | Per Program | ||||||||||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||
| Development regulatory and commercial milestones receivable | $ 350,000,000 | |||||||||
| Apellis Pharmaceuticals, Inc | ||||||||||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||
| Agreement description | In June 2021, the Company entered into a research collaboration agreement, or the Apellis Agreement, with Apellis Pharmaceuticals, Inc., or Apellis, focused on the use of certain of the Company’s base editing technology to discover new treatments for complement system-driven diseases. Under the terms of the Apellis Agreement, the Company will conduct preclinical research on six base editing programs that target specific genes within the complement system in various organs, including the eye, liver, and brain. Apellis has an exclusive option to license any or all of the six programs, or in each case, an Opt-In Right, and collectively, the Opt-In Rights, and will assume responsibility for subsequent development. The Company may elect to enter into a 50-50 U.S. co-development and co-commercialization agreement with Apellis with respect to one program instead of a license. The collaboration is managed on an overall basis by an alliance steering committee formed by an equal number of representatives from the Company and Apellis. | |||||||||
| Collaboration arrangement, initial term | 5 years | |||||||||
| Collaboration agreement performance obligation revenue period for recognition | 5 years | |||||||||
| Collaboration agreement aggregate transaction price | $ 75,000,000 | |||||||||
| Collaboration agreement performance obligation revenue recognized | 6,300,000 | 2,900,000 | 11,700,000 | 8,200,000 | ||||||
| Upfront fee receivable upon signing contract | $ 50,000,000 | |||||||||
| Collaboration agreement first anniversary amount receivable | $ 25,000,000 | |||||||||
| Current portion of deferred revenue | 14,900,000 | 14,900,000 | ||||||||
| Apellis Pharmaceuticals, Inc | Maximum | ||||||||||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||
| Collaboration arrangement extension term | 2 years | |||||||||
| Orbital | ||||||||||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||
| Agreement description | Under the terms of the Orbital Agreement, the Company will collaborate with Orbital to advance nonviral delivery and ribonucleic acid, or RNA, technology by providing Orbital with certain proprietary materials, a non-exclusive research license to certain RNA technology and nonviral delivery technology controlled by the Company, and by performing research and development support services as outlined in a research plan. The Company also granted Orbital an exploitation license to certain RNA technology and nonviral delivery technology controlled by the Company. The exploitation license is exclusive in the fields of vaccines and certain protein therapeutics and nonexclusive in all other fields other than gene editing and conditioning. The collaboration is managed on an overall basis by a Joint Steering Committee, or JSC, comprised of an equal number of representatives from the Company and Orbital. | |||||||||
| Common stock shares received at closing | 75 | |||||||||
| Collaboration agreement performance obligation revenue period for recognition | 3 years | |||||||||
| Collaboration agreement aggregate transaction price | $ 25,500,000 | |||||||||
| Collaboration agreement performance obligation revenue recognized | 2,100,000 | $ 2,100,000 | 4,200,000 | $ 4,200,000 | ||||||
| Current portion of deferred revenue | $ 2,100,000 | $ 2,100,000 | ||||||||
| Orbital | Exploitation Licenses | ||||||||||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||
| Collaboration arrangement, initial term | 3 years | |||||||||
| Collaboration arrangement extension term description | which may be extended for up to two successive one-year periods | |||||||||
| Orbital | Research Plan | ||||||||||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||
| Collaboration arrangement, initial term | 3 years | |||||||||